Tubulysin E is primarily utilized in the field of cancer research due to its potent antitumor activity. It functions by disrupting microtubule dynamics, which are essential for cell division, thereby inhibiting the proliferation of cancer cells. This makes it a valuable tool in studying the mechanisms of microtubule-targeting agents and their potential therapeutic applications. Additionally, Tubulysin E is being explored in the development of antibody-drug conjugates (ADCs), where it is linked to antibodies that specifically target cancer cells, enhancing the precision and efficacy of cancer treatments while minimizing damage to healthy tissues. Its strong cytotoxic properties also make it a candidate for investigating new strategies in chemotherapy and overcoming drug resistance in various cancer types.